Valuation: Enimmune corporation

Market Cap 1.2B 37.13M 32.61M 30.32M 27.83M 52.28M 3.58B 53.09M 360M 141M 1.76B 139M 136M 6.08B P/E 2024
-11.3x
P/E 2025 -9.04x
Enterprise Value 1.15B 35.44M 31.13M 28.95M 26.56M 49.91M 3.41B 50.68M 344M 134M 1.68B 133M 130M 5.8B EV / Sales 2024
35.4x
EV / Sales 2025 29.7x
Free-Float
28.72%
Yield 2024 *
-
Yield 2025 -
1 week+2.78%
Current month+4.06%
1 month+7.77%
3 months-14.40%
6 months-17.16%
Current year-19.17%
1 week 16.25
Extreme 16.25
17.1
1 month 15.4
Extreme 15.4
17.1
Current year 15.4
Extreme 15.4
22.15
1 year 15.4
Extreme 15.4
23.9
3 years 14.65
Extreme 14.65
49.3
5 years 14.65
Extreme 14.65
75.3
10 years 14.49
Extreme 14.49
125
Manager TitleAgeSince
Chief Executive Officer - 07/01/2019
Chief Tech/Sci/R&D Officer - 21/07/2014
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 17/06/2020
Chairman - 07/01/2019
Director/Board Member - 02/01/2014
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.78%-1.48%-64.80% 37.13M
+0.93%+6.97%+59.60%+69.78% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
-0.46%-1.29%+2.86%+425.15% 23.18B
-2.97%-2.35%-22.53%-15.34% 22.59B
-0.61%+1.57%+21.44%-7.26% 20.46B
-1.34%+0.51%+26.03%-28.68% 17.56B
-0.10%+1.88%+34.42%+545.91% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
-0.50%-0.98%+21.43%+179.36% 13.92B
Average -0.83%+1.18%+35.32%+149.57% 24.01B
Weighted average by Cap. -0.81%+2.10%+39.18%+136.71%

Financials

2024 2025
Net sales 39.92M 1.23M 1.08M 1.01M 925K 1.74M 119M 1.76M 11.97M 4.68M 58.42M 4.63M 4.53M 202M 48.19M 1.49M 1.31M 1.22M 1.12M 2.1M 143M 2.13M 14.45M 5.65M 70.53M 5.59M 5.47M 244M
Net income -158M -4.87M -4.28M -3.98M -3.65M -6.86M -469M -6.96M -47.24M -18.45M -231M -18.28M -17.89M -797M -164M -5.08M -4.46M -4.15M -3.81M -7.15M -489M -7.26M -49.27M -19.25M -241M -19.07M -18.66M -832M
Net Debt -382M -11.81M -10.37M -9.65M -8.85M -16.63M -1.14B -16.89M -115M -44.75M -559M -44.33M -43.37M -1.93B -54.59M -1.69M -1.48M -1.38M -1.26M -2.38M -163M -2.41M -16.37M -6.4M -79.9M -6.34M -6.2M -276M
Logo Enimmune corporation
ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.
Employees
-
Date Price Change Volume
24/07/26 TWD 16.65 0.00% 38,305
23/07/26 TWD 16.65 -0.89% 38,561
22/07/26 TWD 16.80 +3.07% 111,227
21/07/26 TWD 16.30 -1.81% 120,785
20/07/26 TWD 16.60 +2.47% 140,006
  1. Stock Market
  2. Stocks
  3. 6564 Stock